BioInvest In The News

Wide World of Stocks (3-16-15)
MarketWatch (2-26-15)
Forbes (2-25-15)
The Money Show (2-25-15)
MoneyShow Five Prime (1-19-15)
Life Sciences Report (12-30-14)
Company Updates
Anthera Update (3-17-15)

Anthera Update (3-17-15)

      Special Update – Anthera (ANTH) – Raising TARGET PRICE to 25 IgAN Positive Interim Look Is Second Straight For B-Mod Update With Management Confirms Improving Fundamentals Stock Sell Off Unwarranted; $92m. mkt cap & 3 Phase IIIs Raising TARGET PRICE to 25 B-Mod IgAN Passes Futility Check – Anthera delivered another positive interim [...]

Pharmacyclics Update (3-5-15)

Pharmacyclics Update (3-5-15)

Special Update – PCYC – A Final Word – It is with bittersweet sorrow that ABBV stepped in to acquire Pharmacyclics at $261.25 per share or $21 billion in a mix of cash and stock. In our 27 years researching biotech stocks, we have never witnessed the creation of wealth in such a short time with the [...]

Pacira Update (3-2-2015)

Pacira Update (3-2-2015)

Special Update – PCRX – FDA Issues Complete Response Letter (CRL) For Nerve Block Indication – Pacira shares are sharply lower (-14%) after the FDA issued a CRL for their application to expand EXPAREL’s label to include infiltration into nerve blocks. The PDUFA date was March 5, and the Company (and us) expected the label expansion [...]